This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
In a tumor mouse model, whole glucan particle (WGP) beta-glucan combined with PD-1/PD-L1-blocking antibodies increased immune cell recruitment, improved the balance between T-cell activation and immune tolerance, and delayed tumor progression compared with checkpoint blockade alone.
Read the original research
β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer.
Frontiers in pharmacology, 2022, 13, 887457
Citation
Wang, Meng; Bai, Yang; Pei, Jinjun; Li, Dongjie; Pu, Xiaolan; Zhu, Wenyu; Xia, Lei; Qi, Chunjian; Jiang, Hua; Ning, Yeshan. (2022). β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer.. Frontiers in pharmacology, 2022, 13, 887457. https://doi.org/10.3389/fphar.2022.887457